Liang Zhao, Haojun Chen, Zhide Guo, Kaili Fu, Lanling Yao, Li Fu, Weixi Guo, Xuejun Wen, Orit Jacobson, Xianzhong Zhang, Long Sun, Hua Wu, Qin Lin, Xiaoyuan Chen
Currently, most patients with non-small cell lung cancer (NSCLC) are diagnosed in advanced stages with a poor five-year survival rate. Therefore, intensive research aimed at finding novel therapeutic strategies has been ongoing; experimental models that reliably emulate NSCLC disease are greatly needed to predict responses to novel therapeutics. Therefore, we developed patient-derived xenograft (PDX) models of NSCLC, which we then used to evaluate the therapeutic efficacy of 177 Lu-EB-RGD, a peptide-based radiopharmaceutical with improved pharmacokinetics that targets integrin αv β3 In this study, three different groups of NSCLC-PDXs were successfully established, all of which maintained the same IHC and genetic characteristics of the human primary tumor...
October 2020: Molecular Cancer Therapeutics